Whole exome sequencing (WES) is a powerful tool to investigate genetic variations underlying cancers, Mendelian diseases, and complex human disorders. Targeting only protein coding regions, WES provides a more cost-effective approach than whole genome sequencing.
GENEWIZ provides comprehensive solutions for exome sequencing at the research and clinical level.
Our research-grade service provides customizable solutions for human and mouse exome sequencing. Flexible service packages are available to meet your budget and deadline requirements.
Our clinical workflows are performed in a CLIA-certified lab by CLIA-trained personnel on CLIA-qualified equipment. Receive the highest level of regulatory compliance with our CLIA-validated clinical exome sequencing assay.
Verify your final targets of interest using GENEWIZ’s confirmatory sequencing service.
Germline variant discovery
Uncovering disease-associated genotypes
Somatic mutation discovery
Tumor/normal sequencing
Exceeding manufacturer's benchmarks
Starting at 1 week for sequencing
Sequencing available at our lab in Leipzig, Germany
Dedicated Ph.D. -level support at every step with real-time project updates through our online system
Flexible data amounts starting at 10M read pairs
Latest platforms - Illumina NovaSeq delivers the highest throughput on the market
Highly scalable - Submit one sample or as many as hundreds
Fragment gDNA, bind probes to exons, and pull down
Add adapters to exon-enriched DNA
Sequence 2x150 bp on Illumina® platform
Identify SNVs, INDELs, gene fusions, and CNVs
Developing immunotherapies for cancer can be difficult due to the variation of immune response from patient to patient. In this webinar, Dr. Litchfield from UCL Cancer Institute presents his team’s exploratory research using a multiomics approach to better understand the diversity of immune response to cancer and highlights their findings of an alternative source of a tumour-specific antigen in checkpoint inhibitor (CPI) response.
US
Europe (English)
Chinese
Japanese
